Home Stocks ThermoGenesis Holdings, Inc. Stock listing
OTC:THMO ThermoGenesis Holdings, Inc. Stock Follow ThermoGenesis Holdings, Inc. into a list and get an email when it puts out news.
Ticker OTC:THMO
Asset type Stock
Exchange OTC
Currency USD ThermoGenesis Holdings, Inc. on 6ix
Calls 7 calls with a replay · 7 with a transcript · latest Nov 13, 2023
Decks 18 decks · latest Jan 10, 2022 On this page Team and board Officers Officer Role Haihong Zhu CEO Chris Xu Executive Chairman of the Board
Board Director Role Chris Xu Executive Chairman of the Board
Events Calls Call When Status ThermoGenesis Holdings (OTC:THMO) Q3 2023 Earnings Call Mon, Nov 13, 2023 · 4:30 PM ET Replay ThermoGenesis Holdings (OTC:THMO) Q2 2023 Earnings Call Thu, Aug 10, 2023 · 4:30 PM ET Replay ThermoGenesis Holdings (OTC:THMO) Q1 2023 Earnings Call Mon, May 15, 2023 · 1:30 PM ET Replay ThermoGenesis Holdings (OTC:THMO) Q4 2022 Earnings Call Thu, Mar 30, 2023 · 4:30 PM ET Replay ThermoGenesis Holdings (OTC:THMO) Q3 2022 Earnings Call Thu, Nov 10, 2022 · 1:30 PM ET Replay ThermoGenesis Holdings (OTC:THMO) Q2 2022 Earnings Call Thu, Aug 11, 2022 · 3:00 PM ET Replay ThermoGenesis Holdings (OTC:THMO) Q4 2021 Earnings Call Mon, Mar 28, 2022 · 4:30 PM ET Replay
Results days Quarter Results Q1 2024 May 17, 2024 · After close Q4 2023 Mar 28, 2024 · After close Q3 2023 Nov 13, 2023 · After close Q2 2023 Aug 10, 2023 · After close Q1 2023 May 15, 2023 · After close Q4 2022 Mar 30, 2023 · After close Q3 2022 Nov 10, 2022 · After close Q2 2022 Aug 11, 2022 · After close Q1 2022 May 19, 2022 · After close Q4 2021 Mar 28, 2022 · After close
All 14 quarters Quarter Results Q3 2021 Nov 12, 2021 · After close Q2 2021 Aug 12, 2021 · After close Q1 2021 May 13, 2021 · After close Q4 2020 Mar 17, 2021 · After close
Open Events
Decks Deck Kind Slides Date H. C. Wainwright BioConnect Conference 2022 Conference 24 slides Jan 10, 2022 H.C. Wainwright 23rd Annual Global Investment Conference 2021 Conference 19 slides Sep 15, 2021 Corporate Update (May 2020) Corporate update 18 slides May 14, 2020 Q3 2019 Earnings Presentation Earnings 26 slides Nov 20, 2019 Cesca Therapeutics — BIO Investor Forum, San Francisco 2019 Conference 25 slides Oct 22, 2019 Cesca Therapeutics — HC Wainwright 21st Annual Global Investment Conference (September 2019) Conference 20 slides Sep 11, 2019 Cesca Therapeutics — BIO CEO & Investor Conference 2019 Conference 21 slides Feb 13, 2019 Cesca Therapeutics — Biotech Showcase 2018 Conference 21 slides Jan 16, 2018 Cesca Therapeutics — Investor Presentation (November 2017) Investor deck 24 slides Nov 15, 2017 Cesca Therapeutics — Presentation to Dawson James Securities (May 2017) Conference 22 slides May 11, 2017
All 18 decks Open Decks
Financials Annual, in USD
Income statement Line FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 Revenue 9.45M 10.5M 9.29M 9.74M 13.0M 9.67M 14.5M 11.9M 16.0M 16.0M Cost of revenue 7.51M 7.77M 5.80M 8.48M 7.35M 7.48M 8.69M 9.19M 11.3M 10.1M Gross profit 1.93M 2.71M 3.49M 1.26M 5.70M 2.19M 5.84M 2.74M 4.75M 5.89M Research and development 1.28M 1.66M 2.21M 2.48M 2.40M 3.01M 2.50M 3.23M 5.94M 3.47M Selling, general and administrative 6.92M 7.24M 8.52M 5.73M 6.38M 8.29M 10.9M 8.23M 10.7M 8.49M Operating income -8.61M -6.19M -7.23M -8.89M -4.73M -43.5M -9.37M -10.9M -14.9M -9.04M Depreciation and amortization 1.15M 926.0K 633.0K 742.0K 805.0K 670.0K 830.0K 1.17M 1.35M 993.0K EBITDA -7.46M -5.27M -6.60M -8.15M -3.93M -42.9M -8.54M -9.70M -13.5M -8.05M Interest expense 10.0M 5.62M 6.10M 7.91M 4.48M 2.70M 20.5M 7.99M 14.0K 6.00K Income before tax -18.9M -11.8M -11.9M -16.8M -10.1M -45.7M -29.8M -18.6M -14.9M -9.03M Income tax 9.14M 5.07M 6.40M 7.44M 3.83M -4.73M -673.0K 7.95M 35.0K -403.0K Net income -18.0M -11.3M -11.4M -16.4M -9.50M -39.7M -29.1M -18.6M -14.9M -8.63M Earnings per share, basic -7.59 -20.45 -43.41 -117.20 -151.09 -971.34 -1,320.40 -2,778.48 -3,312.96 -3,206.17
Balance sheet Line FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 Cash and equivalents 2.00M 4.18M 7.28M 7.16M 3.16M 2.40M 3.62M 5.83M 3.36M 14.8M Receivables 949.0K 1.86M 733.0K 1.38M 1.28M 1.51M 3.70M 3.17M 5.13M 4.69M Inventory 1.41M 3.33M 5.37M 5.88M 3.48M 4.49M 3.62M 3.59M 4.60M 5.61M Current assets 5.18M 10.9M 15.0M 15.3M 9.52M 8.63M 11.2M 12.8M 13.3M 25.3M Property, plant and equipment 1.83M 2.15M 2.03M 2.56M 3.00M 2.33M 2.96M 2.94M Goodwill 0 781.0K 781.0K 781.0K 781.0K 781.0K 13.2M 13.2M 13.2M 13.3M Total assets 11.2M 19.4M 20.7M 20.9M 15.2M 14.6M 46.9M 49.9M 50.8M 62.9M Accounts payable 948.0K 820.0K 1.28M 1.37M 1.45M 2.42M 1.60M 2.65M 5.08M 3.59M Current liabilities 11.8M 11.5M 6.35M 6.14M 6.68M 6.37M 4.52M 5.54M 7.95M 6.38M Long-term debt 9.24M 6.63M 1.41M 1.17M 6.70M 3.50M 2.49M Total debt 10.6M 10.4M 10.5M 7.68M 5.69M 3.39M 7.69M 3.95M 3.19M Total liabilities 14.8M 16.1M 17.3M 15.0M 14.3M 7.88M 16.1M 17.6M 15.9M 14.2M Shareholders' equity -3.58M 3.32M 3.40M 5.87M 916.0K 6.73M 30.8M 32.3M 34.9M 48.7M Shares outstanding 2.37M 551.0K 262.1K 139.5K 62.9K 40.9K 22.0K 6.69K 4.48K 2.69K
Cash flow Line FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 Cash from operations -3.72M -7.28M -6.62M -14.4M -3.26M -6.98M -7.21M -9.63M -10.6M -7.84M Capital spending -1.73M -400.0K -93.0K -23.0K -182.0K -1.24M -375.0K -710.0K -587.0K -402.0K Free cash flow -5.45M -7.68M -6.71M -14.4M -3.44M -8.22M -7.59M -10.3M -11.2M -8.24M Cash from investing -93.0K -23.0K -182.0K -1.24M -1.40M -375.0K -710.0K -587.0K Cash from financing 3.28M 4.59M 6.83M 17.4M 4.20M 7.11M 5.37M 12.8M -189.0K 15.8M Dividends paid -3.63M -17.0M Share buybacks 12.5M 910.0K 6.66M -134.0K -8.00K -129.0K -68.0K Change in cash -2.18M -3.10M 119.0K 3.00M 757.0K -1.11M -2.21M 2.48M -11.5M 7.93M
Open Financials
Cap table Built by 6ix from ThermoGenesis Holdings, Inc.’s releases
Common shares 15,847,517
Fully diluted 15,847,517 Fully diluted Line Shares Common shares 15,847,517
Share count over time Count Shares Nov 22, 2026 15,847,517
Open Cap table
People 6ix reads each seat by machine from the page it links to, and can misread one.
Person Seat Russell M MedfordOther companies:
Atherogenics Inc (President & CEO, Director · Feb 21, 2006 – Dec 31, 2007 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past) Director · Jun 4, 2020 – Jun 4, 2020 · Past Vivian Liu Director · Jun 21, 2022 – Jun 21, 2022 · Past Biao Xi Director · Jul 14, 2023 – Jul 14, 2023 · Past Chris Xu Executive Chairman of the Board · Since at least Nov 5, 2026 Debra Donaghy Director · Dec 31, 2019 – Jun 4, 2020 · Past Haihong Zhu CEO · Since at least Jan 13, 2022 James Xu Director · Jul 14, 2023 – Jul 14, 2023 · Past Jeffery Cauble Chief Financial Officer · Jun 4, 2020 – May 27, 2021 · Past Mark Westgate Director · Jun 4, 2020 – Jun 4, 2020 · Past Thomis Joseph Director · Jun 4, 2020 – Jun 4, 2020 · Past
All 11 people Person Seat Xiaochun Xu CEO, Director · Dec 20, 2019 – Jun 28, 2024 · Past
Open People
Log in to ask 6ix AI your own questions about ThermoGenesis Holdings, Inc.